Grace Therapeutics, Inc. (GRCE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $36.81M
Last updated: Nov 17, 2026 at 4:15 PM ET
Grace Therapeutics, Inc. (GRCE) Statistics
Grace Therapeutics (GRCE) has a market cap of $36.81M and an enterprise value of $15.50M. Its share count is up 26.33% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 57.89% below the market cap, as cash exceeds debt.
| Market Cap | $36.81M |
|---|---|
| Enterprise Value | $15.50M |
| Latest price (Nov 17, 2026) | $1.72 |
Key Dates
| Last Earnings Date | Nov 12, 2026 |
|---|---|
| Fiscal Year End | March |
Valuation Ratios
| P/B Ratio | 0.6x |
|---|---|
| P/TBV Ratio | 1.8x |
Price Statistics
The stock is down 43.79% over 52 weeks and trades 13.57% below its 50-day average.
| Beta (1Y) | 0.95 |
|---|---|
| 52-Week Change | -43.79% |
| 1-Month Change | -8.51% |
| 3-Month Change | -21.82% |
| 6-Month Change | -20.00% |
| Total Return (1Y) | -43.79% |
| Return vs SPY (1Y) | -57.13% |
| Max Drawdown (1Y) | -66.47% |
| Max Drawdown (3Y) | -66.47% |
| Sharpe Ratio (1Y) | -0.73 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $1.99 |
| 200-Day Average | $2.71 |
| 52-Week Range | $1.67 to $5.18 |
| RSI (14 Days) | 35.0 |
| Average Volume (20 Days) | 112.82K |
Financial Position
Current assets cover 13.61x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 13.61x |
|---|---|
| Quick Ratio | 13.61x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -40.15% over the last 12 months, against a 5-year average of -31.34%.
| Return on Equity (ROE) | -40.15% |
|---|---|
| Return on Assets (ROA) | -38.61% |
| ROE (5Y Average) | -31.34% |
| ROA (5Y Average) | -27.30% |
| ROIC (5Y Average) | -21.19% |
Scores
GRCE has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | -$24.45M |
| Pretax Income | -$23.98M |
| Net Income | -$22.28M |
| Reported EPS (TTM) | -$1.29 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 96.15% of the $57.70M in total assets.
| Cash and Equivalents | $21.31M |
|---|---|
| Total Debt | $0 |
| Net Cash | $21.31M |
| Net Cash Per Share | $1.06 |
| Working Capital | $20.35M |
| Shareholder Equity | $55.48M |
| Book Value Per Share | $2.76 |
| Tangible Book Value | $19.75M |
| Tangible Book Per Share | $0.98 |
| Total Assets | $57.70M |
| Total Liabilities | $2.22M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $0 of capital spending, operating cash flow left -$8.93M of free cash flow.
| Operating Cash Flow | -$8.93M |
|---|---|
| Capital Expenditures | $0 |
| Free Cash Flow | -$8.93M |
| FCF Per Share | -$0.42 |
| Depreciation and Amortization | $8.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -19.93% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -14.77% |
Dividends and Yields
GRCE does not pay a dividend. Its free cash flow yield is -25.81%.
| FCF Yield | -25.81% |
|---|---|
| Shareholder Yield | 0.00% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About GRCE
What is GRCE's market cap?
Grace Therapeutics has a market cap of $36.81M. Its enterprise value, which adds debt and subtracts cash, is $15.50M.
How many shares of GRCE are outstanding?
Grace Therapeutics has 20.12M shares outstanding. The count is up 26.33% from a year earlier.
Does GRCE pay a dividend?
No. Grace Therapeutics does not pay a dividend.
How much debt does GRCE have?
Grace Therapeutics has $0 of total debt and $21.31M of cash and equivalents, a net cash position of $21.31M.
GRCE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors